"Crispr Therapeutics and Editas are very interesting names that own — exactly how much of the IP they own is still in dispute, because as you can imagine with this much potential earnings and profits at stake, there is massive litigation around it — but they are going to end up with some big quantity of the intellectual property, both of those names," Jabusch said.
But their exuberance about these firms is not just from the intellectual property for viral disease vaccines, Jabusch said. It's also about their intellectual property for many other types of illnesses. Jabusch continued: "This is radically disruptive, and the ownership of that IP is going to make a lot of people incredibly wealthy. And the time to own those stocks is now before they make those announcements. If you wait so long until they're in the index, well they've already made three or four of those announcements. Go ahead and get started.